Forward Looking Statements
2
Certain statements in this presentation are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actualresults, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any suchforward-looking statements. These factors include, among other things, the impact of the COVID-19 pandemic, the conditions in the U.S. and global economy, the markets served by us and thefinancial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in U.S. policy stemming from the U.S. administration, such as changes inU.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, fluctuations in inventory of our distributors andcustomers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services,the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices andthe health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require newmarketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummateappropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating toacquisitions, investments and divestitures, significant restrictions and/or potential liability based on tax implications of transactions with Danaher, security breaches or other disruptions of ourinformation technology systems or violations of data privacy laws, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risksrelating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicableto multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to implement and maintain effectiveinternal control over financial reporting, risks relating to product, service or software defects, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjustpurchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, the impact of regulation on demand for our products and services, labormatters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom’s decision to leave the EU), disruptions relating to war, terrorism,widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, pension plan costs, and our ability to attract, develop and retain talentedexecutives and other key employees. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SECfilings, including our Annual Report on Form 10-K for fiscal year 2019 and our Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this presentationand except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future eventsand developments or otherwise.
24%
48%
22%
6%
EM NA W-EU ROW
All financial metrics based on 2019 unless otherwise indicated; all pie chart percentages are % of 2019 sales; ROW = rest of world
1: Adj. EBITDA Margin is a non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measure, please see Appendix.
Revenue by segment
Revenue by channel
Revenue by geography
Outstanding brand portfolio with decades of industry expertise
Strong global growth drivers:• Aging of global population • Growing middle class in
Emerging Markets• Digitization of the dental practice• Increased focus on aesthetics
51%
49%
Equipment & Consumables
Specialty Products & Technologies
>70% Consumables
Distributor50%
Direct50%
TOTAL 2019 REVENUE
2019 ADJ. EBITDA MARGIN1
$2.8B
Mid-teens
2019 GROSS MARGIN~55%
3
Portfolio positioned for “new normal”
85% of Envista revenue in consumables or small equipment
Orthodontics
Implants & Biomaterials
Consumables
Small Equipment
Large Imaging Equipment
Treatment Units
4
Total Sales:~$1.3B
EBITDA Margin*: >20%
Channel: >90% Direct
Total Sales: ~$1.4B
EBITDA Margin*: >10%
Channel: >85% Distribution
Equipment and ConsumablesSpecialty Products & Technologies
All financial metrics based on 2019 unless otherwise indicated* EBITDA Margin is a non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measure, please see Appendix.
Our foundation
5
PurposeWHY WE ARE HERE
PromiseWHAT WE PROMISE
We partner with professionals to improve lives We champion creators of confidenceCore Values
WHAT WE BELIEVE
Customer Centricity Innovation Respect Continuous
Improvement LeadershipPowered by
Envista Business SystemHOW WE WORK
Lean Innovation Growth Leadership
EBS drives Envista transformation
EBS driving significant transformation over the past five years
EBS Pillar Pre - 2016 2020Lean Complex
organizationOrganization simplification - 10 OpCos to 3 OpCos- >230 sites to <100 sites- Execution of $100M permanent cost reduction initiatives
Innovation Limited innovation and new product launches
Accelerated innovation- DTX, N1, and Spark now commercially launched- Broader roll out continuing in ’21
Growth Competing brands Portfolio simplification- Imaging/Treatment Unit brands from 11 to 5 - Exit of lower growth/margin business including Pelton & Crane and
Latin America Treatment Unit businesses
Leadership Lack of continuity in leadership
- Core leadership team in place since 2016- >200 years combined Envista and Dental market experience
6
Leveraging EBS to create long-term value
Positioned to accelerate growthas a leader in some of the most attractive segments of Dental
Significant opportunity to
expand marginsthrough operating
leverage, productivity initiatives and
improving portfolio mix
Flexible capital structure and strong cash flow profile for
M&A to further improve growth
profile
Building a differentiated Envista 7
Driving sustainable long-term core growth*
Clear path to accelerate growth to MSD over time
E&C
2019 Core Growth Long-Term Growth Drivers
• Higher consumable mix – Infection prevention growth / P&C exit
• DTX software driving imaging and integrated workflow adoption
• Greater adoption in implant and orthodontic market
• New product innovation – Spark and N1
Specialty LSD >MSD
-LSD LSD
Envista Flat MSD • Expansion in DSO market• Growing Emerging Markets
presence
8*These are not projections and do not constitute guidance; they are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these results will be achieved and the Company undertakes no duty to update this information. Core Growth is a non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measure, please see Appendix
Growing in Infection Prevention
Infection prevention added >200bps of revenue growth in Q3 2020
Infection Prevention Revenue
2019 Future Target
$175M
$275M+
Geographic Expansion
Market Expansion
Medical share gain
2020 market grew >10% due to increased infection prevention compliance
Leverage global footprint: U.S. is ~80% of Envista infection prevention revenue
New products, capacity and OEM certification to improve share: Envista has <10% share in medical vs. >40% share in Dental
>50%
9
Specialty Products & Technologies
Orthodontics and Implants are significantly underpenetrated markets
500M
15M
Potential cases Actual ortho treatments / year
<3% treated
Orthodontics
4B
200M
<20M
People w/ toothloss
Seek treatment(annually)
Receive implant*(annually)
<10%
Implants
Market Size:$5.5B
Aligner Growth: >20%
B&W Growth: Flat/LSD
Market Size: $5.5B
Market Growth:MSD
10 Source: WHO, iData, Management estimates; (*) Avg. 1.5-2 implants per treatment
How we win in Orthodontics
Building a $400M+ business positioned to grow revenue DD with >20% EBITDA margins*
>20% of 2020E sales from new products launches in past 3 years
Orthodontic Core Sales Growth
2018 2019 Q3 2020
MSDLSD/MSD
DD
B&W Market
• >250% increase in cases in 2H’20E vs 1H’20• >1,000 active orthodontists • Anticipate HSD contribution to orthodontic revenue growthInnovation
Education
Geographic Exposure
Annually >500 events and >75,000 clinicians trained
>70% of 2020E sales outside of US
11*These are not projections and do not constitute guidance; they are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these results will be achieved and the Company undertakes no duty to update this information.
How we win in Implants
>1,300 direct “Feet on the Street”; Annually >750 events and >100,000 clinicians trained
Leader in clinical and digital workflow innovation
Expand in higher growth biomaterials/value implant markets, < 20% of Envista implant revenue 2020E
Clinical Advantages
N1 Implant System
• Drill speed 50 rpm vs >1,000 rpm1
• Drill protocol – 80% of implants placed in 2 steps
• Trioval implant shape reduces stress and promotes faster osseointegration2
• Shorter learning curve, easier to train
2020 Progress
• >300 doctors now using in >10 EU countries; 2/3rds repeat customers
• Not yet available for sale in the United States
12
Innovation
Education
Capital Deployment
Innovation and commercial execution to accelerate growth to MSD+ over time*1 Conventional2 Internal pre-clinical data
*These are not projections and do not constitute guidance; they are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these results will be achieved and the Company undertakes no duty to update this information.
# Non-ortho employees # Ortho employeesApr '20 Dec '20
Improving margin and investing for growth
Visibility to expand to high-teens and above EBITDA* margin over time
2020 Cost Reduction Program
Headcount Reduction
Indirect Spend and Real Estate
$100Mannualized
savings
Headcount Reduction & Redeployment
Planned investment in Specialty
>$30M $ capacity and commercial
investment ’21 vs ‘19
13
Site consolidation in 2020
Closed >10 sites
Additional MFG Facility
1
*EBITDA is a projection and does not constitute guidance. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these results will be achieved and the Company undertakes no duty to update this information.
>10% >40%
Capital deployment priorities
14 I
Opportunity to thoughtfully deploy capital on M&A while continuing to de-lever
Opportunity to accelerate
2003 - 2015
# M&A deals
2016 - 2020
>25
3
Improving balance sheet
2017 – 2019FCF* >$1B Q3 2019 Q3 2020
$1.3B
$1.1B
$ Net Debt**
~20% reduction
14 *FCF is a non-GAAP financial measures. For a reconciliation to the most directly comparable GAAP measures, please see Appendix.**Net debt is calculated as gross debt, plus bank overdrafts, less debt discounts and issuance costs, and cash.
Consumables and workflow-oriented portfolio
Imaging$0.4B*
Software / Treatment Planning
SpecialtyConsumables
$1.3B*
Traditional Equipment
$0.3B*
Traditional Consumables
$0.6B*
Treatment Units
Instruments/Handpieces
Infection Prevention RestorativeEndodontics
>85% of Envista positioned in high value workflow solutions and consumables15 *All financial metrics based on 2019 unless otherwise indicated; Traditional equipment excludes the revenue from exited treatment center and instrument business
Summary
Transforming Envista into a workflow and consumables focused portfolio
Core sales growth1,2
Flat in 2019 to +MSD long-term
Acquisition growth~$1B free cash flow (2017-2019)
Margin expansion1
Visibility to expand EBITDA margin2
to high-teens and above over time
Continuous improvementEBS is how we work
161 These are not projections and do not constitute guidance; they are growth drivers and are subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and are based upon assumptions with respect to future decisions, which are subject to change. Actual results will vary and those variations may be material. Nothing in this presentation should be regarded as a representation by any person that these drivers will be achieved and the Company undertakes no duty to update this information.2 : Core sales growth, free cash flow and EBITDA margin are non-GAAP financial measure. For a reconciliation to the most directly comparable GAAP measure, please see Appendix.
Reconciliation of Adjusted EBITDA
(unaudited)($ in millions)
Year EndedDecember 31
2019
Reported Net Earnings (GAAP) $217.6
Interest expense, net 3.5
Income taxes 57.9
Depreciation 39.0
Amortization 89.5
EBITDA (Non-GAAP) $407.5
Accruals for significant legal matters 9.0
Separation costs 4.2
Adjusted EBITDA (Non-GAAP) $420.7
Sales $2,751.6
EBITDA Margin (EBITDA/Sales) 14.8%
Adjusted EBITDA Margin (Adjusted EBITDA/Sales) 15.3%
Reconciliation of EBITDA by segment
(unaudited)($ in millions)
Year Ended December 31
2019
Specialty Products &
Technologies
Equipment & Consumables
Operating profit $227.7 $105.8
Depreciation 17.7 19.6
Amortization 57.7 31.8
EBITDA (Non-GAAP) $303.1 $157.2
Sales $1,342.7 $1,408.9
EBITDA Margin (EBITDA/Sales) 22.6% 11.2%
Reconciliation of Free Cash Flow(unaudited)($ in millions)
Year Ended December 31
2019 2018 2017
Net cash used in investing activities (GAAP) ($78.4) ($75.5) ($54.9)
Net cash provided by (used in) financing activies (GAAP)
($107.7) ($324.6) ($304.2)
Net cash provided by (used in) operating activities (GAAP)
$397.5 $400.1 $359.1
Less: payments for additions to property plant & equipment (capital expenditures) (GAAP)
(77.8) (72.2) (48.9)
Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)
1.6 - 0.1
Free Cash Flow (Non-GAAP) $321.3 $327.9 $310.3
Reconciliation of Core Sales GrowthConsolidated (unaudited) % Change Year Ended December 31, 2019 vs.
Comparable 2018 PeriodTotal sales growth (3.5%)Less the impact of:Discontinued products 1.0%Currency exchange rates 2.5%Core sales growth -%
Specialty Products & TechnologiesTotal sales growth (2.0%)Less the impact of:Discontinued products 1.5%Currency exchange rates 2.0%Core sales growth 1.5%
Equipment & ConsumablesTotal sales growth (4.5%)Less the impact of:Discontinued products 1.0%Currency exchange rates 2.5%Core sales growth (1.0%)
We use the term “core sales” to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary of the acquisition (“acquisitions”), (2) sales from discontinued products and (3) the impact of currency translation.Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the netdecline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the period-to-periodchange in sales after applying current period foreign exchange rates to the prior year period. We use the term “core sales growth” to refer to the measure of comparing current period core sales with the corresponding period of the prior year.